PMV Pharmaceuticals heads into its May 15 investor call with a conflicting set of signals: a Q1 earnings beat, a short-interest spike, and fresh analyst caution.
The most notable piece of recent Street activity came today. Oppenheimer's Jeff Jones lowered his price target on PMVP from $6 to $5 — maintaining his Outperform rating but reducing headroom on a stock already trading at $1.42. That target of $5 implies more than 250% upside from current levels, a gap that reflects how far the shares have fallen from prior expectations rather than near-term optimism. HC Wainwright has held a Buy with a $5 target through multiple reiterations over the past two years, keeping the analyst consensus firmly bullish even as the stock has ground lower. The mean price target of $4.50 puts the entire sell-side well above where the stock trades — a setup that more often signals accumulated disappointment than genuine conviction.
Short interest tells the more animated story entering this week. Bears have stepped up meaningfully — SI climbed roughly 71% over the past month to reach nearly 5% of the free float, with an 11% jump just in the last week alone pushing shares short to around 2.57 million. That single-month acceleration is the sharpest buildup in the 30-day window captured in the data. Despite the increase, the borrow market is far from stressed. The cost to borrow is modest at 0.64% — well below the March highs near 1.5% — and availability remains ample, with the lending pool nowhere close to full at the current pace of demand. This is a stock where shorts are rebuilding positions at low cost, not one where bears are fighting over scarce inventory.
Options positioning adds an interesting contrast to the short-side buildup. Calls dominate options activity by an extreme margin — the put/call ratio of 0.0053 is actually the 52-week low, sitting more than one standard deviation below its 20-day average of 0.0074. That means options traders are leaning bullish (or at least not hedging), even as short sellers add to their positions. The two signals are pulling in opposite directions, and the divergence will likely resolve around tomorrow's event. The Q1 print from Monday showed a beat — EPS of -$0.34 against an estimate of -$0.39 — which may account for some of the call-heavy positioning.
On the ownership side, BML Capital Management holds nearly 10% of shares and added over 1.8 million shares in Q1 2026. Sio Capital similarly added around 440,000 shares in the same quarter. These are meaningful increments for a company of this size, and they suggest at least some institutional players have been adding into weakness. The most recent insider data, however, is stale — the last reported trades go back to October 2025, when OrbiMed Advisors sold 1 million shares at $1.52. No fresh insider signal is available in the window.
Prior earnings reactions give some context for what the call tomorrow might bring. The February 2026 Q4 print produced a dramatic move — shares jumped 31% the following day and held a 20% gain over the subsequent five sessions. The March 2026 event (likely a pipeline update) generated a more modest 6.5% one-day move. The pattern suggests PMVP can move sharply on catalysts, though reactions have been highly variable in size. The short score has drifted higher this week, reaching 46.6 from around 44 earlier in the month — a modest but notable tick-up that aligns with the short-interest increase. What the May 15 call reveals about the pipeline and cash position will determine whether those newly-added short positions face pressure to cover or find validation.
See the live data behind this article on ORTEX.
Open PMVP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
